Hosted on MSN10d
Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer
THURSDAY, Oct. 31, 2024 (HealthDay News) -- Inavolisib plus palbociclib-fulvestrant yields significantly longer ...
Targeted Oncology9d
Inavolisib Regimen Continues to Improve Survival in PIK3CA-Mutated Breast Cancer
The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.
Mena FN24d
Novartis Receives Positive CHMP Opinion For Kisqali® To Help Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer
et al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine ...
Pharmabiz16d
Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines
In MBC, Kisqali has consistently demonstrated statistically significant overall survival benefit ... menopausal patients with HR+/HER2- advanced breast cancer. Further, Kisqali in combination with ...
Mena FN24d
Novartis Receives Positive CHMP Opinion For Kisqali® To Help Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer
In the trial, Kisqali plus endocrine ... significant overall survival benefit across three Phase III trials16-26. The NCCN Guidelines® for breast cancer recommend ribociclib (Kisqali) as the ...
Pharmabiz23d
EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
In the EU, Kisqali is approved for the treatment of women with HR+/HER2- advanced or MBC in combination with either an AI or fulvestrant ... overall survival benefit across three phase III trials. The ...
pharmaphorum1d
Routine NHS access to Ibrance assured with new NICE guidance
"After a median follow-up of 73.3 months in the trial, median overall survival was 6.8 months longer in people who had palbociclib plus fulvestrant ... people with advanced breast cancer who ...
Seeking Alpha11d
Arvinas, Inc. (ARVN) Q3 2024 Earnings Call Transcript
This is a randomized open label multicenter trial of Vepdeg versus fulvestrant in patients with ER+/HER2- advanced breast cancer whose ... measures include overall survival, anti-tumor activity ...